A Case of Recalcitrant Epidermolysis Bullosa Acquisita Responsive to Rituximab Therapy

Authors

  • Sophia K. McKinley B.A.,

    1. Harvard Medical School, Children's Hospital Boston, Boston, Massachusetts
    Search for more papers by this author
  • Jennifer T. Huang M.D.,

    Corresponding author
    1. Department of Pediatrics, Harvard Medical School, Children's Hospital Boston, Boston, Massachusetts
    2. Department of Dermatology, Harvard Medical School, Children's Hospital Boston, Boston, Massachusetts
    • Address correspondence to Jennifer T. Huang, M.D., Fegan 6, 300 Longwood Ave., Boston, MA 02115, or e-mail: jenhuang711@gmail.com.

    Search for more papers by this author
  • Jennifer Tan M.D.,

    1. Department of Pediatrics, Harvard Medical School, Children's Hospital Boston, Boston, Massachusetts
    2. Department of Dermatology, Harvard Medical School, Children's Hospital Boston, Boston, Massachusetts
    Search for more papers by this author
  • Daniela Kroshinsky M.D., M.P.H.,

    1. Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Stephen Gellis M.D.

    1. Department of Pediatrics, Harvard Medical School, Children's Hospital Boston, Boston, Massachusetts
    2. Department of Dermatology, Harvard Medical School, Children's Hospital Boston, Boston, Massachusetts
    Search for more papers by this author

  • The patient has provided permission to publish the features of his case and his identity has been protected.

Abstract

Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disorder that occurs infrequently in children. Although typically associated with a good prognosis in children, there are rare cases that are refractory to treatment with conventional immunosuppressive therapy. Rituximab, an anti-CD20 monoclonal antibody, has been reported to be effective in the adult form of EBA. We report a case of a child with severe and recalcitrant EBA exhibiting a sustained response to treatment with rituximab.

Ancillary